Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Dean Discusses Ongoing Research on Biomarkers in MCL

November 27th 2018

Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).

Cohen Discusses Future of MCL Treatment

November 20th 2018

Jonathon B. Cohen, MD, discusses the evolving landscape of mantle cell lymphoma.

Dr. Cohen Discusses CAR T-Cell Therapy in MCL

November 20th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.

Expert Explains Treatment Approaches for MCL

November 15th 2018

Simon Rule, MD, PhD, discusses the observational and active therapeutic approaches for patients with mantle cell lymphoma.

Future of MCL Treatment May Lie in Combinations, CAR T-Cell Therapy

November 14th 2018

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

Dr. Wang Discusses New Agents in the Field of MCL

November 7th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses new agents in the field of mantle cell lymphoma (MCL).

Dr. Rule on Patients With p53-Mutated MCL

November 7th 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical Center, United Kingdom, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Shah on Challenges in Treating Patients With High-Risk MCL

November 6th 2018

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the challenges in treating patients with high-risk mantle cell lymphoma (MCL).

Dr. Dean on the Evolution of Treatment Approaches in MCL

November 3rd 2018

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

Dr. Rule Addresses Questions on the Watch-and-Wait Approach in MCL

October 31st 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, addresses questions on the watch-and-wait approach in mantle cell lymphoma.

UCSF Expert Highlights Progress in Lymphoma Landscape

October 29th 2018

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Dr. Cohen on the Potential of BTK Inhibitors in Frontline Treatment of MCL

October 27th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the potential of Bruton tyrosine kinase (BTK) inhibitors in the frontline treatment of patients with mantle cell lymphoma (MCL).

Dr. Shah on Challenges of CAR T-Cell Clinical Trials in MCL

October 17th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Dr. Wang Discusses the Treatment of Relapsed/Refractory MCL

October 16th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Cohen Discusses Combination Therapy in MCL

October 12th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Expert Explains Latest Advances in Hodgkin Lymphoma, MCL

October 9th 2018

Chaitra S. Ujjani, MD, discusses the latest progress in both Hodgkin lymphoma and mantle cell lymphoma.

Dr. Rule on Watching and Waiting Approach For MCL Subset

October 3rd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the “watching and waiting” approach for a subset of patients with mantle cell lymphoma.

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCL

October 2nd 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

September 30th 2018

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection

September 29th 2018

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.